New findings suggest salivary HHV-6 levels may be a good biomarker of QOL in patients during the course of chemotherapy.
HHV-6 may play a significant role in patients with Bell’s Palsy
Study finds high prevelence, high viral loads of HHV-6 in patients with Bell’s Palsy
HHV-6B protein DR6 identified as inducer of cell cycle arrest in G2/M
Dr. Hollsberg’s team at Aarhus University in Denmark has identified the protein responsible for this crucial mechanism of cell-cycle specific interruption.
TNF-α predicts HHV-6 reactivation and disease progression in patients with DIHS/DRESS
While elevated TNF-a detected at the early onset of disease is a strong indicator for the early recognition of HHV-6 reactivation, this finding also reflects important therapeutic information that could be used as an early diagnostic marker of DIHS/DRESS.
Mixed and compartmentalized infections found in Japanese stem cell transplant patients
A team of Japanese investigators led by Tetsushi Yoshikawa found evidence of mixed infections of human herpesvirus 6B (HHV-6B) in two out of 15 stem cell transplant patients.
Understanding the association between ciHHV-6 and HIV disease
HIV+ individuals with ciHHV-6 may experience lower severity HIV disease.
Spotlight on Horvat & Reynaud from INSERM
Branka Horvat, MD, PhD, Director of Research at the International Centre for Infectiology Research in Lyon, France (INSERM), and her doctoral student Josephine Reynaud have recently published an important paper on a new transgenic mouse model
Acute and recurrent urticaria now associated with HHV-6
HHV-6 and other herpesviruses may be involved in the development of acute or recurrent acute urticaria.
Activation of ciHHV-6 by telomeric circle formation
Additional evidence that shortened telomeres can cause the release and possible activation of integrated HHV-6.
Measles immunosuppression may cause abortive, subclinical reactivation of HHV-6
Dr. Yoshizo Asano and colleagues in Japan report that in measles immunosuppression, cells sensitized to HHV-6B immediate early and early antigen proteins may suppress replication cycles and virus formation, resulting in an “incomplete” subclinical state of reactivation.
New HHV-6 reagent available from The HHV-6 Foundation: DR7 Mab
We are pleased to announce that with the help of a few HHV-6 specialists, especially Prof. Louis Flamand from Canada, we have generated the monoclonal antibody DR-7.
Q & A with Dr. Bhupesh Prusty and Professor Thomas Rudel
Dr. Bhupesh Prusty and Professor Thomas Rudel from Biozentrum University have published several articles on the phenomenon of ciHHV-6 activation including a study on the interaction between Chlamydia infection and ciHHV-6. We interviewed them about the implications of these findings, their current studies, and what lies ahead for this team in the field of ciHHV-6 research.
ciHHV-6 low in Quebec children with ALL and absent in controls
The frequency of ciHHV-6 in the Province of Quebec (Canada) appears to be lower than that observed in US and UK.
REVIEW: Important differences between the HHV-6A and HHV-6B viruses
An international group of experts summarize the significant differences between the two viruses.
Chimerix “SUPPRESS” trial to be largest ever for HHV-6 treatment
Chimerix “SUPPRESS” trial to be largest study ever conducted for treatment of HHV-6 infection